StocksMedium•5 November 2026•
1 min read
Pfizer Partners with Flagship Pioneering for Autoimmune Disease Research
Key Facts
1Pfizer and Flagship Pioneering's Pioneering Medicines unit announced a collaboration to identify and develop novel, selective inhibitors for autoimmune diseases.
Pfizer and Flagship Pioneering's Pioneering Medicines unit announced a collaboration to identify and develop novel, selective inhibitors for autoimmune diseases. Benzinga reported that the partnership aims to leverage Flagship's innovation platform to expand Pfizer's pipeline in the high-growth immunology and inflammation sector.
Pfizer (PFE) closed at $30.79 on November 4, 2026, with the stock reaching a day high of $30.9 and a low of $30.04 during that session. The agreement reflects Pfizer's strategy to bolster its research and development capabilities through strategic alliances with scientific innovation engines focused on transformative products.